


Systemic mastocytosis with an associated hematological neoplasm masquerading as overt primary myelofibrosis

Rebecca Z. Xu, University of British Columbia; and Zhaodong Xu, Royal Jubilee Hospital



A 62-year-old woman was investigated for myeloproliferative neoplasm with splenomegaly. Complete blood count showed the following: hemoglobin, 123 g/L; leukocytes, $30.7 \times 10^9/L$; platelets, $273 \times 10^9/L$; myelocytes, $1.14 \times 10^9/L$; neutrophils, $23.72 \times 10^9/L$; eosinophils, $0.43 \times 10^9/L$; and basophils, $1.02 \times 10^9/L$. She had no skin lesions/lymphadenopathy, but lactate dehydrogenase was elevated (416 U/L). Peripheral blood (PB) showed a leukoerythroblastosis with teardrops and rare blasts. Aspirate was unsuccessful. Biopsy was hypercellular with megakaryocytic hyperplasia and atypia (panel A; original magnification $\times 40$, hematoxylin and eosin stain) and focally increased eosinophils and MF-3 fibrosis (panel B; original magnification $\times 40$, reticulin stain). CD34 showed $<1\%$ blasts. CD117 highlighted multifocal infiltrates of spindle-shaped/atypical

mast cells (≥ 15) in aggregates (panel C; original magnification $\times 40$) with positive tryptase/CD25 (panel D; original magnification $\times 40$). JAK2 was positive and c-Kit on PB and BCR-ABL was negative. These findings fulfilled the major and 2 minor criteria for systemic mastocytosis (SM) and the 3 major and 4 minor criteria for overt primary myelofibrosis (PMF). The diagnosis was consistent with SM with an associated hematological neoplasm (SM-AHN) per 2016 World Health Organization criteria.

Compared with other SM-AHN, SM with associated PMF is relatively rare, likely because it can be easily missed as a result of dry tap and fibrosis. The case highlights the importance of careful inspection of biopsy and applying CD117 staining initially to unfold the disguised SM-AHN.